Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure

Cardiac involvement in systemic amyloidosis (AL) occurs in ~50% of all AL patients. However once symptomatic heart failure develops, therapeutic options are limited thereby conferring a poor overall prognosis. The median survival is <6 months when AL patients are untreated for the underlying plasma cell dyscrasia. We thus sought to identify risk factors of increased mortality in treatment - naïve , AL cardiac amyloidosis with heart failure....